ReviewInternational journal of molecular sciences2026
Hereditary Pancreatic Cancer: Genetic Risk, Surveillance Strategies, and Therapeutic Implications.
Mariapia Marafioti, Margherita Patruno, Martina Musarra, Nicola Silvestris, Jessica Alejandra Portillo Funes, Fausto Omero, Elena Sapuppo, Vincenzo Cianci, Marco Calabrò, Natasha Irrera and 3 more
Abstract readReview
In one paragraphReview in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Mariapia MarafiotiSchool of Specialization in Medical Oncology, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.ORCID 0009-0007-8807-6163 Margherita PatrunoCenter for Study of Heredo-Familial Tumors, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.ORCID 0000-0001-8231-596X Martina MusarraDivision of Oncology "Gaetano Martino" Hospital, University of Messina, 98122 Messina, Italy.ORCID 0009-0001-4728-7569 Nicola SilvestrisMedical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.ORCID 0000-0001-7814-7318 Jessica Alejandra Portillo FunesSchool of Specialization in Medical Oncology, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.
Fausto OmeroSchool of Specialization in Medical Oncology, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.ORCID 0009-0001-4202-3855 Elena SapuppoMedical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.ORCID 0009-0005-0801-7362 Vincenzo CianciDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Legal Medicine, University of Messina, 98125 Messina, Italy.ORCID 0009-0003-1274-3514 Marco CalabròDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98125 Messina, Italy.ORCID 0000-0003-2082-9855 Natasha IrreraDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Silvana BriugliaDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98125 Messina, Italy.ORCID 0000-0002-5213-441X Mariacarmela SantarpiaDivision of Oncology "Gaetano Martino" Hospital, University of Messina, 98122 Messina, Italy.
Desirèe SperanzaDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.ORCID 0009-0005-5108-1052 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a rising incidence and a poor prognosis that largely reflects late-stage diagnosis. Although most cases are sporadic, approximately 5-10% of PDACs occur in the context of inherited cancer susceptibility, including hereditary pancreatic cancer (HPC) syndromes and familial pancreatic cancer (FPC). Germline pathogenic variants in genes involved in DNA damage repair, cell-cycle regulation, and genomic stability-such as
Indexed as
Carcinoma, Pancreatic DuctalGenetic Predisposition to DiseasePancreatic NeoplasmsCarcinomaGenetic TestingGerm-Line MutationHumansgenetic testinggermline pathogenic variantshereditary pancreatic cancerpancreatic cancerPDACsurveillancetargeted treatment
Identifiers
PMID42511746
PMCPMC13410001
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390